



Swiss Heart Valve Meeting

5th of November 2026

5th Edition – Radisson Blu Lucerne



SGK 7 Credits
SGHC 7 Credits

Programme 2026

www.swissheartvalve.ch



Sponsors

Platin



Edwards

Gold



Medtronic



Silver



Bronze



Donato

CoRRect Medical Switzerland GmbH

Programme/Registration

www.swissheartvalve.ch

Organiser/Congress Office

andfrank ag

Walzmühlestrasse 49a

CH-8500 Frauenfeld

Phone +41 56 648 28 00

office@swissheartvalve.ch



Dear colleagues,

It is our great pleasure to welcome you to the 5th edition of the Swiss Heart Valve Meeting in Lucerne.

This current program offers a comprehensive overview of the evaluation and management of valvular heart disease, with particular emphasis on contemporary challenges like a gender-based approach, durability of devices and emerging therapeutic strategies. Special focus will be placed on advances in transcatheter interventions, complex case discussions, and the role of the heart team in clinical decision-making.

The Swiss Heart Valve Meeting continues to serve as an interactive platform where cardiologists, interventionalists, cardiac surgeons, and imaging specialists can exchange expertise, discuss real-world cases, and refine patient-tailored treatment strategies. As in previous years, active participation and interdisciplinary dialogue remain key elements of the meeting.

We are grateful to our sponsors for their continued and generous support, and we are honoured to welcome distinguished international experts who will share the latest developments, evidence, and insights from daily clinical practice.

We hope you will enjoy the program and look forward to welcoming you in person in Lucerne at the Radisson Hotel, ideally located near the lake and the train station.

The detailed program is available online at www.swissheartvalve.ch.

Yours sincerely, The Scientific Committee

Prof. Dr. med. Peter Wenaweser
HerzKlinik Hirslanden Zürich

Prof. Dr. med. Stefan Toggweiler
Herzzentrum Kantonsspital Luzern

Prof. Dr. med. Fabien Praz
Inselspital, Universitätsspital Bern

Prof. Dr. med. Enrico Ferrari
Istituto Cardiocentro Ticino

Prof. Dr. med. Olivier Muller
CHUV Lausanne





Agenda

08:15	Welcome coffee
08:25	Objectives of the course

Session 1: 20 Years of TAVI in Switzerland, where do we stand?

08:30	Swiss TAVI registry: results in perspective with Europe and USA
08:40	Discussion
08:45	Which valve for which anatomy; what can we learn from CT and Echo
08:55	Discussion
09:00	Debate - TAVI in all asymptomatic patients: pro - TAVI in all asymptomatic patients: contra
09:20	Discussion
09:30	Durability of biological valves: update and outlook
09:45	Discussion

Session 2: Women and valvular heart disease

10:00	Debate - SAVR or Tavi in women: the evidence - Are we ready for a sex-specific approach?
10:20	Discussion
10:30	Coffee break





Session 3: Evidence for valvular heart disease: recent papers changing my practice

10:50	TAVI: latest publications impacting clinical practice
11:00	Discussion
11:05	M-TEER and T-TEER: latest publications impacting clinical practice
11:15	Discussion
11:20	Surgery in valvular heart disease: latest publications impacting clinical practice
11:30	Discussion

Session 4: Heart Team Battle 1

11:35	Multivalvular heart disease: severe AS and MR <ul style="list-style-type: none">- Case presentation (Hirslanden Aarau)- How would we treat (HUG)- How did we treat (Hirslanden Aarau)
11:50	Challenging failed biological aortic valve <ul style="list-style-type: none">- Case presentation (HUG)- How would we treat (Hirslanden Aarau)- How did we treat (HUG)
12:05	Lunch





Session 5: Transcatheter valve replacement; where do we stand?

12:50	TMVR: update and outlook
13:00	Discussion
13:05	TTVR: update and multidisciplinary approach
13:20	Discussion
13:25	Debate: Treatment of aortic regurgitation - Surgery is the best option - Transcatheter solutions offer excellent alternatives
13:45	Discussion

Session 6: Complex TAVI and M-TEER/T-TEER cases

13:55	TAVI in a bicuspid valve
14:03	Discussion
14:07	TAVI: low coronary take-off in a valve in valve case
14:15	Discussion
14:19	M-TEER: barlow disease
14:27	Discussion
14:31	T-TEER: a huge gap
14:39	Discussion
14:45	Coffee break





Session 7: Medical treatment in valvular heart disease

15:15	Medical treatment for VHD: impact of the new guidelines for the chronic heart failure
15:30	Discussion
15:40	NOAC for better durability of biological valves?
15:50	Discussion

Session 8: Heart Team Battle 2

15:55	Case presentation LUKS <ul style="list-style-type: none">- Case presentation (LUKS)- How would we treat (Cardiocentro)- How did we treat (LUKS)
16:10	Case presentation Cardiocentro <ul style="list-style-type: none">- Case presentation (Cardiocentro)- How would we treat (LUKS)- How did we treat (Cardiocentro)
16:25	Closing Remarks
16:30	End of Congress
16:30	Apéro

